| Drug ID: | Drug122 |
|---|---|
| Drug Name: | Empagliflozin |
| CID: | 11949646 |
| DrugBank ID: | DB09038 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT05610956, , NCT05058417 |
| Molecular Formula: | C23H27ClO7 |
| Molecular Weight: | 450.9 g/mol |
| Isomeric SMILES: | C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl |
| Synonyms: | Empagliflozin; 864070-44-0; JARDIANCE; BI 10773; BI10773; BI-10773; Empagliflozina; Empagliflozine; UNII-HDC1R2M35U; HDC1R2M35U |
| Phase 0: | 9 |
| Phase 1: | 189 |
| Phase 2: | 109 |
| Phase 3: | 149 |
| Phase 4: | 125 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1012 | 11949646 | Empagliflozin | 6524 | SLC5A2 | Homo sapiens (human) | Sodium/glucose cotransporter 2 inhibitor | |
| dt1013 | 11949646 | Empagliflozin | 6524 | SLC5A2 | Homo sapiens (human) | 21985634 | Inhibition |
| dt1014 | 11949646 | Empagliflozin | 6523 | SLC5A1 | Homo sapiens (human) | 21985634 | Inhibition |
| dt1015 | 11949646 | Empagliflozin | 6527 | SLC5A4 | Homo sapiens (human) | None | |
| dt1016 | 11949646 | Empagliflozin | 916 | CD3E | Homo sapiens (human) | Inhibitor | |
| dt1017 | 11949646 | Empagliflozin | 6524 | SLC5A2 | Homo sapiens (human) | Inhibitor | |
| dt1018 | 11949646 | Empagliflozin | 8678 | BECN1 | Rattus norvegicus (Norway rat) | 35654124 | Empagliflozin inhibits the reaction [rotenone results in decreased expression of BECN1 protein] |
| dt1019 | 11949646 | Empagliflozin | 847 | CAT | Rattus norvegicus (Norway rat) | 35654124 | Empagliflozin inhibits the reaction [rotenone results in decreased activity of CAT protein] |
| dt1020 | 11949646 | Empagliflozin | 1649 | DDIT3 | Rattus norvegicus (Norway rat) | 35654124 | Empagliflozin inhibits the reaction [rotenone results in increased expression of DDIT3 mrna] |
| dt1021 | 11949646 | Empagliflozin | 9451 | EIF2AK3 | Rattus norvegicus (Norway rat) | 35654124 | Empagliflozin inhibits the reaction [rotenone results in increased phosphorylation of EIF2AK3 protein] |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| ChiCTR2400080773 | Study on the efficacy of empagliflozin in children with glycogen storage disease associated inflammatory bowel disease | Not Available | Recruiting | Guangdong Provincial People's Hospital | Glycogen storage disease associated inflammatory … | Experimental group:Empagliflozin; | Details |
| NCT05078879 | A Phase 1 Study of Empagliflozin as Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency | PHASE1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | Crohn's Disease;Glycogen Metabolism;Inflammatory … | Drug: Empagliflozin | Details |
| NCT05058417 | Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis | PHASE2 | RECRUITING | Sadat City University | Ulcerative Colitis | DRUG: Empagliflozin 10 MG|DRUG: Placebo | Details |
| NCT05610956 | Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis | EARLY_PHASE1 | NOT_YET_RECRUITING | Tanta University | Ulcerative Colitis | DRUG: Empagliflozin|DRUG: conventional treatment | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Empagliflozin as treatment in glycogen storage disease type IB patients
PMID: 40416752
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Glycogen Storage Disease Ib (GSD Ib) is a disease that associates both neutropenia and neutrophil dysfunction, thereby causing recurrent …
Spontaneous restoration of premature ovarian insufficiency and conception in a …
PMID: 40399615
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Glycogen storage disease type 1b (GSD-1b) is a rare genetic disorder characterized by deficiencies in glucose metabolism, leading to severe hypoglyce…
Case report: The success of empagliflozin therapy for glycogen storage disease …
PMID: 38919482
Year: 2024
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Glycogen storage disease type 1b (GSD-1b) is characterized by neutropenia and neutrophil dysfunction generated by the accumulation of 1…
Empagliflozin in children with glycogen storage disease-associated inflammatory…
PMID: 38622211
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Glycogen storage disease type Ib (GSD-Ib) is a rare inborn error of glycogen metabolism caused by mutations in SLC37A4. Patients with GSD-Ib are at h…
Clinical Remission of Severe Crohn's Disease with Empagliflozin Monotherapy in …
PMID: 38034420
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Glycogen storage disease type 1b (GSD1b) is associated with inflammatory bowel disease and congenital neutropenia. Neutropenia in GSD1b is caused by …
Crohn-like disease long remission in a pediatric patient with glycogen storage …
PMID: 37779861
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Glycogen storage disease type Ib (GSD Ib) is a rare hereditary glycogen disorder that results in inadequate maintenance of glucose homeostasis, accum…
Current understanding on pathogenesis and effective treatment of glycogen stora…
PMID: 37152929
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Glycogen storage type Ib (GSDIb) is a rare inborn error of metabolism caused by glucose-6-phosphate transporter (G6PT, SLC37A4) deficiency. G6PT defe…
Empagliflozin attenuates intestinal inflammation through suppression of nitric …
PMID: 37086302
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel diseases (IBD) are characterized by chronic and relapsing inflammation affecting the gastrointestinal (GI) tract. The incidence an…
Favorable outcome of empagliflozin treatment in two pediatric glycogen storage …
PMID: 36507137
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Glycogen storage disease type 1b (GSD1b) is an ultra-rare autosomal recessive disorder, caused by mutations in SLC37A4 gene. Affected pat…
Repurposing of Empagliflozin as a Possible Treatment for Neutropenia and Inflam…
PMID: 36039216
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Glycogen storage disease type Ib (GSD-Ib) is an autosomal-recessive inborn error of carbohydrate metabolism, where severe fasting hypoglycemia is ass…
The overall benefits of empagliflozin treatment in adult siblings with glycogen…
PMID: 35982912
Year: 2022
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Recently published case reports suggest the benefit of empagliflozin use in subjects with glycogen storage disease Ib (GSD Ib). METHODS…
Untargeted metabolomic profiling in a patient with glycogen storage disease Ib …
PMID: 35822097
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Glycogen storage disease type Ib (GSD-Ib) is a rare inborn error of glycogen metabolism uniquely associated with neutropenia and neutrophil dysfuncti…
Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data …
PMID: 35503103
Year: 2022
Relationship Type:
Treatment
Score: 6.5
PURPOSE: This paper aims to report collective information on safety and efficacy of empagliflozin drug repurposing in individuals with glycogen stora…
Preventive empagliflozin activity on acute acetic acid-induced ulcerative colit…
PMID: 35218923
Year: 2022
Relationship Type:
Mechanism
Score: 6.5
BACKGROUND: Ulcerative colitis (UC) is a chronic colon inflammation that is linked to exposure to environmental factors leading to improper immune re…
Interference With the AMPKα/mTOR/NLRP3 Signaling and the IL-23/IL-17 Axis Effec…
PMID: 34489707
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Empagliflozin and metformin are widely used for the treatment of type 2 diabetes. These drugs showed marked anti-inflammatory effects in different an…
Improved inflammatory bowel disease, wound healing and normal oxidative burst u…
PMID: 32838757
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Glycogen storage disease type Ib (GSD Ib) is a rare inborn error of glycogen metabolism due to mutations in SLC37A4. Besides a severe for…